Immune Thrombocytopenia (ITP)

Hematology·MeSH: Purpura, Thrombocytopenic, Idiopathic

Prevalence

30.0 / 100K

17 drugs in development·11 companies·5 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
doptelet	AKORN INC (AKRX)
promacta	Novartis AG (NVS)
promacta kit	Novartis AG (NVS)
tavalisse	RIGEL PHARMACEUTICALS INC (RIGL)

Phase 3(3)

Phase 2(5)

Drug	Company
budoprutug	Climb Bio, Inc. (CLYM)
sar445088	Sanofi (SNY)
thrombopoietin receptor agonist	Merus N.V. (MRUS)
thrombopoietin receptor agonist	NOVARTIS AG (NVSEF)
thrombopoietin receptor agonist	Novartis AG (NVS)

Early Phase 1(1)

Drug	Company
QT-019C	Filana Therapeutics Inc. (FLNA)

Phase 4(4)

Drug	Company
Efgartigimod IV	ARGENX SE (ARGX)
efgartigimod iv or efgartigimod ph20 sc	ARGENX SE (ARGX)
ianalumab	Novartis AG (NVS)
Pirtobrutinib	ELI LILLY & Co (LLY)

BioSniper tracks 17 drugs in development for Immune Thrombocytopenia (ITP) across 11 companies.

There are 5 clinical trials targeting Immune Thrombocytopenia (ITP) tracked by BioSniper.

The estimated prevalence of Immune Thrombocytopenia (ITP) is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.